China Pharma Trade Up 4.22% in Q1 2026 as Exports Lead Growth

China's pharmaceutical and healthcare product trade posted steady growth in the first quarter of 2026, with exports continuing to outpace imports and reinforcing the sector's resilience amid a broader global trade recovery.

According to customs data, total trade in pharmaceutical and healthcare products reached $49.135 billion in Q1, up 4.22% year-on-year. Exports rose 5.51% to $28.124 billion, while imports increased 2.54% to $21.011 billion, resulting in a trade surplus of $7.114 billion. The faster expansion in exports underscores the industry's strengthening international competitiveness.

Compared with China's overall goods trade growth of roughly 15% over the same period, the sector's more moderate pace reflects the relatively inelastic demand for healthcare products and lower volatility. It also signals a transition phase marked by structural adjustment and a shift toward higher-quality growth rather than rapid expansion.

Structural Shift Toward High-Value Exports

Export dynamics in Q1 continued trends seen in 2025, with medical devices leading growth, supported by stable performance in active pharmaceutical ingredients (APIs), a surge in finished drug formulations, and pressure on traditional Chinese medicine (TCM) exports.

Medical devices emerged as the primary growth engine, with exports rising 8.92% year-on-year to $12.585 billion, outpacing the industry average. Key categories — including diagnostic and treatment equipment, disposable medical supplies, rehabilitation products, and dental devices — recorded broad-based growth, supported by China's integrated supply chains, stable production capacity, and competitive pricing.

Pharmaceutical exports totaled $14.287 billion, up 3.4%, with ongoing structural optimization. API exports reached $10.894 billion, accounting for nearly 40% of total exports and maintaining their role as a core pillar. While bulk APIs such as vitamins, penicillin, and antipyretic analgesics declined due to global price fluctuations and rising competition, growth in hormones, anti-infective agents, and cephalosporins helped stabilize overall API performance.

Finished pharmaceutical products posted strong expansion, with exports surging 41.53% to $2.396 billion. Notably, hormone-based drugs recorded a sharp 173.58% increase, while other anti-infective and penicillin-based formulations achieved double-digit growth. The surge highlights an accelerating shift toward higher value-added formulations.

In contrast, TCM exports declined 2.35% to $1.253 billion, with extracts and proprietary Chinese medicines falling 5.99% and 8.92%, respectively. Only herbal materials, decoction pieces, and health supplements registered modest growth.

Overall, China's pharmaceutical export structure is evolving toward a model characterized by stable APIs, rapidly expanding formulations, and leading medical devices, with high-value products increasingly driving growth.

Diversified Market Expansion Strengthens Resilience

Export markets in Q1 showed a more balanced structure, with traditional markets remaining stable and emerging markets expanding rapidly, enhancing overall resilience to external risks.

Developed economies — including the European Union, the United States, Japan, and South Korea — continued to account for nearly 60% of China's pharmaceutical exports. These markets remain key destinations for high-end formulations and medical equipment due to strong demand and regulatory recognition. Although growth has moderated amid rising protectionism and intensified local competition, their strategic importance remains intact.

Emerging markets, particularly those participating in the Belt and Road Initiative (BRI), became the strongest growth driver. Exports to BRI countries recorded double-digit growth, with robust demand from ASEAN, Russia, the Middle East, Latin America, and Africa. Policy support, improved infrastructure, and free trade agreements have amplified the competitiveness of Chinese products, driving deeper market penetration across APIs, TCM products, medical consumables, and rehabilitation devices.

Data indicates that export growth to emerging and developing markets consistently outpaced the industry average, effectively offsetting weaker momentum in traditional markets. At the same time, exports to free trade partners and zero-tariff markets expanded rapidly, reducing costs and improving market access.

The result is a more diversified export footprint, with multiple growth engines helping to mitigate external uncertainties.

Opportunities and Challenges Ahead

China's pharmaceutical trade faces a complex landscape of both opportunities and constraints.

On the challenge side, intensifying global competition — particularly from India and the European Union in APIs — continues to pressure market share. Western companies maintain advantages in high-end pharmaceuticals and advanced medical equipment. At the same time, rising regulatory barriers, including stricter certification requirements, environmental standards, and intellectual property protections, are increasing compliance costs.

Structural issues persist, including relatively low value-added in some export segments, limited global brand influence, and a high reliance on OEM and raw material exports, which constrain pricing power. Additionally, fluctuations in TCM raw material prices, rising supply chain costs, and logistics inefficiencies are weighing on profitability.

However, growth opportunities remain significant. Global aging populations, rising chronic disease prevalence, and continued improvements in public health systems are driving sustained demand. China's advancing innovation capabilities — particularly in innovative drugs, high-end medical devices, and biopharmaceuticals — are accelerating overseas expansion and enhancing global competitiveness.

Further tailwinds include deeper healthcare cooperation under the BRI framework, rapid growth in cross-border e-commerce, and an expanding network of free trade agreements. Against the backdrop of global supply chain restructuring, China's strengths in complete industrial chains, stable supply, and scalable manufacturing are becoming increasingly prominent.

Outlook: Steady Growth with Structural Upgrading

Looking ahead, China's pharmaceutical trade is expected to enter a phase focused on stable scale, optimized structure, improved quality, and enhanced efficiency.

In the near term, the sector is projected to maintain steady growth through the rest of 2026, with total trade expected to expand by 5% to 6%, outpacing the global industry average. Finished pharmaceuticals and diagnostic equipment are likely to remain the main growth drivers, while API capacity undergoes gradual optimization. TCM exports may see a modest recovery supported by policy measures.

Over the medium to long term, export structures are expected to further upgrade, with high-value products gaining a larger share. Market diversification will deepen, with BRI and emerging markets becoming as important as traditional destinations. At the same time, innovation-driven products — such as novel drugs and advanced medical devices — are set to become new hallmarks of China's export portfolio, supported by digitalization, intelligent manufacturing, and green transformation.

Despite persistent risks from exchange rate volatility, geopolitical tensions, and technical trade barriers, sustained investment in innovation, branding, and market expansion will be critical for China's transition from a major pharmaceutical trader to a global industry leader.